Clinical Trial Update: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) [Phase 2]

View source ↗

Summary

Phase II trial evaluating ridaforolimus with exemestane versus ridaforolimus, dalotuzumab, and exemestane in breast cancer was completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• Exemestane (Exemestane)
• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2019-03-25